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Pathophysiology of  the  edema
Diabetic  retinopathy  (DR)  is  the  leading  cause  of  irreversible
blindness  in people  of  a  productive  age in devel-
oped  countries,  macular  edema  being  (DME)  primarily
responsible.1 DME  occurs  through  the alteration  of  the
blood--ocular  barrier  (BRB),  with  a  multifactorial  mechanism
secondary  to  changes  in cellular junctions,  loss  of pericytes
and  endothelial  cells, dilation  of retinal  vessels,  leukosta-
sis  and  vitreoretinal  traction.2,3 In  general,  it is  due to  the
increase  in  inflammatory  factors,  such as  prostaglandins  and
specific  proinflammatory  interleukins,  and  angiogenic  sub-
stances  which  include  vascular  endothelial  growth  factor
(VEGF).  Decreases  of the anti-angiogenic  retinal  pigment
epithelium  derived-factor  (PEDF)4 also  contribute  to  this
mechanism.
Diagnosis
DME  diagnosis  is  clinically  performed  by  fundoscopy;  when
the  center  of  the macula  (fovea  centralis)  is  thickened  or
swollen,  this  is  referred  to as  a  clinically  significant  central-
involved  macular  edema  (CI-CSME)  and when  it is  unaffected
we  refer  to  is  as  a  clinically  significant  non-central-involved
macular  edema  (NCI-CSME).  Fluorescent  angiography  (FAG)
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is  a contrast  study  which confirms  the  presence  of  DME  and
classifies  it  as  focal  and  diffuse,  which  guides  the  patho-
physiology.  Focal  DME  is  the result  of internal  BRB  damage
(microaneurisms),  whereas  diffuse  DME  is  linked  mainly  to
external  BRB  damage  (pigment  epithelium  of  the retina).
Some  patients  can  display  DME  with  both  angiographic  pat-
terns.  FAG  remains  the  ‘‘gold  standard’’  when  deciding  DME
treatment;  nevertheless,  in a  publication  about the  value
of  FAG in the  planning  of  DME  treatment,  we  found  that
the  capability  of the specialist  to  decide  the  treatment  with
laser  after  photographic  analysis  without  FAG  matched  with
the  analysis  based on  FAG in 85.7%  of cases and  showed  slight
variations  between  both  analyses  in  14.3%.5 Despite  the  fact
that  FAG is  very  useful  clinically,  it does not contributes  that
much  to  the evaluation  of  retinal  morphology  and  its thick-
ening  pattern. In 1991,  the optical  coherence  tomography
(OCT)  was  patented,  and  nowadays  is  an essential  com-
plement  to  the ophthalmoscopy  and  FAG  in  patients  with
DME.  OCT  is  currently  the  most  precise  technique  for  in vivo
measurement  of  retinal  thickness  and the  analysis  of  vitreo-
macular  interface,  being  key  in diagnosis  and  monitoring  of
treatment.
Treatment
Treatment  is  focused  on  reestablishing  BRB, modulating
inflammatory  and  angiogenic  factors.  The  Early  Treatment
Diabetic  Retinopathy  Study  (ETDRS)  proved  there  was  a
reduction  of  50%  in the risk  of  moderate  vision  loss  when
treating  the  edema  with  a threshold  laser  (from  24%  to
12%  at 3 years),  increasing  the possibility  of  obtaining  a
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slight  visual  improvement.  However,  in diffuse  DME  this
improvement  is  limited.  Recently,  the use  of  vascular  growth
factor  antagonists  (anti-VEGFs)  in intravitreal  injections
has  proven  to reduce  neurovascularization  and  DME,  with
better  results  than  laser  monotherapy  (REVEAL,  RESTORE,
VIVID,  VISTA,  DA VINCI,  BOLT,  etc.).  The  laser  acts  as  a
modulator  of substances  like  PEDF  and  VEGF,  in addition
to  the  thermal  destruction  of  the  external  layers  of  the
retina,  and  reduces  metabolic  demand  and  oxygen  expen-
diture,  with  the  consequent  reduction  of  VEGF.  Anti VEGFs
selectively  block  VEGF.  Bevacizumab  (BVZ)  (AvastinTM)  is  a
recombinant  humanized  monoclonal  (IgG1)  antibody  which
unites  all  VEGF-A  isoforms  and  has  been  used  off-label  via
intravitreal  injection  since  2005  in different  angioprolif-
erative  pathologies.  Ranibizumab  (RBZ)  (LucentisTM)  is  a
humanized  antibody  fragment  directed  against  all  VEGF-A
isoforms,  manufactured  exclusively  for  its  intravitreal  use.
Ranibizumab  was  approved  by  the  FDA  in  2012,  and  by
the  Federal  Commission  for the Protection  of Sanitary  Risks
(COFEPRIS  by  its  Spanish  acronym)  in 2014, for  its  intraoc-
ular  use  in  DME  treatment.  Aflibercept  (AFB)  (EyleaTM in
USA/WetliaTM in  Mexico)  is  a  recombinant  fusion  protein,
consisting  of  fractions  of  domains  of the human  recep-
tors  of  VEGF  type  1 and  2. It  attaches  to  VEGF-A  and  the
Placental  Growth  Factor  (PGF)  in a  sort  of  ‘‘bait  recep-
tor’’,  avoiding  its  interaction  with  native  VEGF  receptors.
It  has  also  been  approved  by  the FDA  (2014),  and  is  pend-
ing  approval  by  COFEPRIS  (by the  end  of  2015)  for  its
intravitreal  use  in  DME.  Multiple  studies  have  proven  the
safety  and  efficacy  of  these  anti-VEGFs  (ANCHOR,  MARINA,
PIER,  PrONTO,  SUSTAIN,  SAILOR, HORIZON,  READ,  RISE,  RIDE,
RESOLVE,  RESTORE,  CATT,  COPERNICO,  GALILEUS,  DA  VINCI,
VIVID,  VISTA,  BOLT,  DRCRnet,  etc.).  In 2011,  the CATT  study
proved  the  safety  and  efficacy  of  RBZ  as  well  as  BVZ  in the
treatment  of  wet-age  related  macular  degeneration  (angio-
proliferative  disease).  Neither  were  statistically  superior
(safety  and  efficacy)  to  the other.  This  study  supported  the
bases  to  continue  the  off-label  use  of  intravitreal  BVZ.  In
March  2015,  the  DRCnet  published  the results  of  their  study,
‘‘Protocol  T’’.  The  study  compared  the safety  and  efficacy
of  these  anti-VEGFs  in  DME.  It reported  an  improvement
in  visual  acuity  in patients  with  central-involved  macular
edema,  but  this  effect  depended  on  the  initial  visual  acu-
ity.  When  initial visual  acuity  loss  was  minor  (20/30  to
20/40),  on average,  there  were  no  apparent  differences
between  the 3 anti-VEGFs.  Nevertheless,  in patients  with
low  initial  visual  acuity  (20/50  or  worse),  AFB  proved  to
be  more  effective  in  visual  acuity  improvement.  Intra-
vitreal  steroids  have  shown  encouraging  results  in the
treatment  of  DME;  they  inhibit  over-regulation  of  inflam-
matory  molecules  and  VEGFs.  There  are  the dexamethasone
intravitreal  implant  (OzurdexTM) and  the  fluocinolone  intra-
vitreal  implant  (lluvienTM),  the  first  one approved  by  the
FDA  and  pending  approval  by  COFEPRIS  (by  the end  of
2015)  for  its  use  in DME.  The  latter  has  been  approved
for  its  use  only  in Europe.  Preservative-free  triamcinolone
(ATLCTM)  is  another  steroid  also  approved  by  the  COFEPRIS
for  intraocular  use.  Nowadays,  steroids  are recommended
for  resistant  cases;  however,  some ophthalmologists  con-
sider  them  as  a  first  line  treatment  or  as  an adjuvant  therapy
to  laser  and  anti-VEGFs.  Because  the  vitreomacular  inter-
face  (posterior  hyaloid  and  inner  limiting  membrane)  plays
an important  role  in  the  development  of  DME,  in tractive  or
non-respondent  cases  its  withdrawal  is  indicated  via vitrec-
tomy.
Different  schemes  in DME  treatment  have  been
described.  Threshold  laser  is recommended  in a  selective
fashion  in a single  use  and,  if necessary,  repeated  in  inter-
vals  of  no  less  than  12  weeks.  Pharmacological  therapy  with
anti-VEGFs  has  been  proposed,  from  having  one  injection
and  repeating  only  when  the ophthalmologist  considers  it
necessary  (Pro  Re  Nata PRN),  to  uninterruptedly  every  4
weeks  for  24  months  (monthly  dose).  Currently,  there  are
two  schemes,  ‘‘treat  and  observe’’  (T&O)  and  ‘‘treat  and
extend’’  (T&E),  the first  one consists  of  applying  a  ‘‘loading
phase’’  of three  anti-VEGF  doses  or  until  accomplishing  the
maximum  visual  effect  and resolution  of  the edema,  with  a
4-week  interval  between  each  injection,  and  after  that  in a
PRN  mode.  In the  latter  (T&E),  after  the ‘‘loading  phase’’,
the  treatment  is  extended  in  rows  of  2 weeks  until  achieving
intervals  no  longer  than  12  weeks.  Re-treatment  or  treat-
ment  extension  criteria  will depend  on  visual  acuity  and
tomography  findings,  loss  (T&O)  or  non-loss  (T&E)  of more
than  five  letters,  or  an  increase  (T&O)  or  decrease  (T&E)  of
macular  thickness  of  over  100  microns.  In  case  of  presenting
edema  reactivation  in  the scheduled  appointment  (T&E),
a  shortened  treatment  is  indicated.  Based  on  the possible
synergy  between  laser,  corticosteroids  and anti-VEGFs,  the
combination  of  these  three  at the  same  time  has  been  pro-
posed,  with  two  intentions;  accomplishing  a  greater  visual
and  anatomical  effect,  and accomplishing  the least  amount
of  treatment  repetition  in the long  term. Nowadays,  there
is  no  exact  algorithm  for  DME  treatment,  thus  it remains  a
debate  topic  in retina  conferences.
My personal approach
Strict  glycemic  and  lipid  controls,  systemic  blood  pressure
and  renal  stability  are fundamental.  I  decide  on  the treat-
ment  depending  on  clinical,  angiographic  and  tomographic
presentations.  Based  on  reports  from  medical  literature,
as  well  as  my personal  experience,6--8 I consider  as  a  first
line  treatment  laser  or  intravitreal  anti-VEGFs  and  intra-
vitreal  steroids  or  vitrectomy  as  a second  line  treatment.
The  anti-VEGFs  I  use  will  depend  on  the  patient’s  eco-
nomic  capabilities;  I  choose  BVZ  in patients  with  limited
economic  resources.  Despite  the fact  that the DRCRnet  sug-
gests  a  superiority  of  AFB  in relation  to  RBZ  in initial  low
vision  cases,  I  usually  begin  with  RBZ,  and  just  in  case  I
do  not  obtain  a good  response,  I  switch  to  AFB  or  BVZ.
Monotherapy  with  anti-VEGFs,  or  in  combination  with  laser,
in  my  experience,  has  proven  to  be superior  to  combined
therapy  with  steroids  (TLC)  during  the  ‘‘loading  phase’’.7
Therefore  unless  it  is  a  case  of  macular  ischemia  (MI)  or
vitreo-proliferative  diabetic  retinopathy  (VPDR),  where  the
laser  (MI) and  the  anti-VEGFs  (MI  and  VPDR)  may  be  ques-
tionable,  I utilize  them  as  first option  of treatment.  In  case
of  chronic  DME  with  little  to  no  response  to  pharmacologi-
cal  (anti-VEGFs  or  steroids)  and  laser  treatment,  either with
or  without  VMI  thickening  and/or  VMTS,  I  indicate  vitrec-
tomy  (Fig.  1). Vitrectomy  is  also  the first  option  treatment
in fibrovascular  tractive  retinal  detachment  with  macu-
lar  involvement  secondary  to  vitreoproliferative  diabetic
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Figure  1 DME  with  a  thickening  of  the  vitroretinal  interface  and  vitromacular  traction  syndrome.
retinopathy.  It  is  important  not to confuse  VMI  thickening  or
VMTS  with  a  macular  involvement  tractive  retinal  detach-
ment.  As  I mentioned  before,  in this case  vitrectomy  is  my
first  option  of  treatment,  contraindicating  even  the use  of
anti-VEGFs  due  to  risk  of  fibrosis  with  detachment  exacer-
bation.  I apply  pan-retinal  photocoagulation  if necessary.
In  case  of  presenting  a NCI-CSME  with  a  good  visual  acuity
(better  than  20/25),  verified  through  FAG  as  a focal  DME
and  an  OCT  showing  a  not  involved  fovea  (Fig.  2), despite
showing  an  anti-VEGF  superiority  over laser  treatment  in
my  experience,8 the  decision  to  use  monotherapy  with  laser
as  a  first  line  treatment  is  my  choice  (risk  of  complication
with  intravitreal  injection).  Different  from  that suggested
by  the  ETDRS,  I  use  the  invisible  or  subthreshold  modified
laser modality  previously  published,9 with  the objective
of  lowering  the complications  of  the  threshold  laser.  It  is
possible  to repeat  this  therapy in intervals  of  no  less  than
12  weeks.  I apply  the laser  as  a modified  ‘‘scatter’’  in the
edema  zone  (respecting  the  foveolar  center)  and, differing
form  multiple  authors  and  the ETDRS,  never  direct  to
microaneurisms.9 I  use  anti-VEGFs,  steroids  or  vitrectomy,
in  that  order,  as  rescue  therapies  (when  there  is  a  poor or
negative  response  with  laser).
In case  of  presenting  a  CI-CSME  with  a slight  decline  in
visual  acuity  (20/30  to  20/40),  verified  through  FAG  as  a
focal  DME,  with  leakage  that  extends  to  the  central  zone
and  an OCT  showing  foveal  involvement  (Fig.  3),  I  suggest  a
combined  therapy  with  anti-VEGFs  and  subthreshold  lasers
in  the microaneurism  zone,  respecting  the foveolar  center.
I  apply  the  laser  1--3  weeks  after  the first injection,  with
Figure  2  Focal  DME  without  foveal  involvement.
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Figure  3  Focal  DME  with  foveal  involvement.
the  objective  of  a possible  reduction  in  the frequency  of
future  re-treatments.  The  injection  scheme  that  I conduct  is
‘‘Treat  &  Extend’’.  If necessary,  I  repeat  the  laser  treatment
with  intervals  of  no  shorter  than  12  weeks  between  each
session.  Steroids  and/or  vitrectomy  are  just in case  of a  poor
or null  response.
In case  of presenting  a  CI-CSME  with  a  bad  visual  acu-
ity  (less  than  20/40),  verified  through  FAG  as  a diffuse  or
mixed  DME  and  an OCT  with  foveal  data  either  in a  bee-
hive  or  petaloid  shape,  or  with  an added  neurosensorial
detachment  (Fig.  4),  monotherapy  with  anti-VEGFs  under
the  ‘‘Treat  & Extend’’  scheme  is  what  I  do.  It  is  important
to  stress  that,  despite  having  a good  response  from  the  first
or second  injection  during  the  ‘‘loading  phase’’,  they  ought
to  be repeated  on  at least  three  occasions  (Fig.  5). In  case
of  a partial  response,  I add  subthreshold  lasers  as  a  rescue
treatment,  with  the  purpose  of  stimulating  the  production
of  PEDF and  obtaining  (by stimulation  of  the epithelium)  a
better  response  to  anti-VEGFs.  In  case  of  a null  response
with  anti-VEGFs,  I do  not  apply  lasers  and  cut  straight  to
steroids.  Given  the case,  if  the patient  shows  positive  results
to  the  steroid  therapy,  the best is  to  try  to  continue  this
stability  returning  to  anti-VEGFs.  If this  is  not  possible,  I
repeat  steroid  treatment  at the  time  of  recurrence.  Similar
to  the other  cases,  if there  is no response  to  medical  ther-
apy  I  perform  a  vitrectomy.  Something  that  may  also  occur,
despite  satisfactory  results  with  an anti-VEGFs,  is  that  the
patient  may  develop  chronical  tachyphylaxis  or  resistance  to
Figure  4 Diffuse  DME  with  a cystic  beehive  pattern  and  neurosensory  detachment.
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Figure  5  Diffuse  DME  with  central  involvement,  pre-  and  post-treatment  with  just  2 doses  of  ranibizumab.
the  anti-VEGF,  suddenly  manifesting  a  negative  response.  In
this  case,  switching  to a  different  anti-VEGF  may  reestablish
a  positive  response.
In  summary,  anti-VEGFs  are currently  the ‘‘gold
standard’’  in  diffuse  DME  treatment.  Laser  remains  as  the
‘‘gold  standard’’  in the treatment  of  focal  DME  without
foveal  involvement.  Likewise,  laser  is  used  as an adju-
vant  therapy  to pharmacological  treatment  (anti-VEGFs  and
steroids).  Steroids  are used in little  or  non-respondent  cases
(with  or  without  VMI  thickening  and/or  VMTS)  resistant  to
first  line  treatment  (laser  and  anti-VEGF)  and  as  an adjuvant
therapy  to this same  therapy.  On  the  other  hand,  steroids
may  apply  as  a first  choice  of  treatment  of  ischemic  DME.
A  vitrectomy  is  indicated  in case  of  chronic  DME  with  lit-
tle  or  no  response  to  pharmacological  and  laser  treatment,
either  with  or  without  VMI  alteration  and/or  VMTS,  and as
a  first  option  of  treatment  in  fibrovascular  tractive  retinal
detachment.
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